Integrating AI with other novel technologies to detect and prevent oesophageal cancer
In the innovative Project DELTA (integrateD diagnostic solution for EarLy deTection of oesophageal cAncer), the PHG Foundation led ethical, and legal research into personalised risk prediction and AI driven pathology to detect oesophageal cancer, and its pre-cursor, Barrett’s oesophagus. Through a collaboration funded by Innovate UK and Cancer Research UK, researchers from Universities of Cambridge, Oxford, King’s College London and Queen Mary’s, working with Cyted, established a new patient pathway, encompassing a novel risk algorithm to identify those at highest risk of developing oesophageal cancer, a novel, non-invasive, nurse administered non-endoscopic sampling device (Cytosponge™-TFF3 test ‘sponge on a string’) and the use of laboratory immunohistochemical assays and an AI digital pathology tool to interpret cellular samples at scale.
The PHG Foundation analysed the ethical, and legal implications potentially arising from these novel elements and from the pathway, through multidisciplinary workshops and cross-cutting research:
Personalised risk prediction
Read: Ethical and legal implications of implementing risk algorithms for early detection and screening for oesophageal cancer, now and in the future. Published in PLOS ONE
Analysis of Cytosponge™ derived samples using AI digital pathology
Read: Ethical and legal considerations influencing human involvement in the implementation of AI in a clinical pathway. Published in Frontiers in Digital Health
Read the Position Statement: Policy recommendations for novel risk stratification, screening and surveillance for oesophageal cancer